Biotech Values

[DewDiligence]

GTCB
Read Me First:

There is sufficient interest in GTCB among readers here that I thought it worthwhile to compile a Read Me First post just for GTCB. I will keep a copy of this post in the iBox at the top of the message-board screen.

The following posts are listed in chronological order. Items in bold-face type are those of particular interest.

#msg-2792299 (Rodman & Renchaw $6 target)
#msg-3007897 (preclinical cancer program)
#msg-3247462 (general info)
#msg-3254155 (general info)
#msg-3444716 (drbio buys)
#msg-3487264 (valuation)
#msg-3543304 (Elan collaborations)
#msg-3587713 (human serum albumin)
#msg-3631094 (bioterror angle)
#msg-3735184 (U.S. ATryn program)
#msg-3737145 (August CC notes)
#msg-3990950 (article in Chemical Market Reporter)
#msg-4057315 (article in The Economist)
#msg-4107224 (IP license to Nexia)
#msg-4281478 (near-term news flow)
#msg-4316445 (bioterror contract with U.S. army)
#msg-4359874 (general info)
#msg-4364077 (comments by urche)
#msg-4372780 (risks of plasma-derived proteins)
#msg-4420831 (webcasts this coming week)